Viking Therapeutics licensed five assets from Ligand Pharmaceuticals, including a clinical-stage type 2 diabetes program that the private San Diego-based company has been working on since it was founded in late 2012.
Viking's maiden voyage began a year and a half ago to develop VK0612, a selective inhibitor of the enzyme fructose-1,...